Ranked after the close on October 30, 2026
Drug Manufacturers - General stocks
Drug Manufacturers - General ranks #27 of 140 industry groups, one of the market's strongest groups, with a median 6-month return of +13% across its 16 US stocks above $1B (sector: Healthcare). 2 of them are in today's top 50 leaders.
#27group rank of 140
+13%median, 6 months
16stocks above $1B
2in the top 50
Drug Manufacturers - General stocks ranked
| # | Stock | Market cap | Off high | Comp | EPS | RS |
|---|---|---|---|---|---|---|
| 1 | LLY Top 50Eli Lilly and Company | $1.26T | 2.2% | |||
| 2 | AMGN Top 50Amgen Inc. | $251.9B | 2.0% | |||
| 3 | ABBVAbbVie Inc. | $521.1B | 1.3% | |||
| 4 | GILDGilead Sciences, Inc. | $211.7B | 2.8% | |||
| 5 | AZNAstraZeneca PLC | $289.5B | 12.3% | |||
| 6 | JNJJohnson & Johnson | $657.7B | 3.1% | |||
| 7 | OGNOrganon & Co. | $3.6B | 0.0% | |||
| 8 | BMYBristol-Myers Squibb Company | $127.7B | 9.0% | |||
| 9 | MRKMerck & Company, Inc. | $368.9B | 4.7% | |||
| 10 | PFEPfizer, Inc. | $174.0B | 0.5% | |||
| 11 | NVSNovartis AG | $303.7B | 5.7% | |||
| 12 | BIIBBiogen Inc. | $37.5B | 2.0% | |||
| 13 | GRFSGrifols, S.A. | $5.5B | 18.2% | |||
| 14 | SNYSanofi | $106.2B | 15.8% | |||
| 15 | GSKGSK plc | $99.2B | 19.8% | |||
| 16 | NVONovo Nordisk A/S | $176.4B | 37.7% |
In order of their Comp rating. The ratings themselves, and the same day's ranking, are for members. Sign in or start for €6.99 a month.
See every rating for €6.99 a month